Antares Therapeutics, formed as a spinout from Scorpion Therapeutics after Lilly’s acquisition, has raised $177 million in a Series A round to continue advancing preclinical oncology drug candidates focusing on previously inaccessible targets. This funding infusion is poised to sustain momentum in tackling challenging cancer targets following strategic portfolio divestments and highlights Lilly's ongoing collaboration with emerging biotech assets.